THE EFFECTS OF THIAZOLIDINEDIONE THERAPY ON NT-PROBNP LEVELS IN PATIENTS WITH TYPE 2 DIABETES

摘要

We sought to determine whether thia-zolidinedione (TZD) therapy affects levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with type 2 diabetes.Materials and Methods: This study population consisted of 76 patients with type 2 diabetes and no history of heart failure. Subjects had NT-proBNP levels determined prior to initiating TZD therapy, and after 3 months of treatment. We compared with in-person changes in NT-proBNP over the 3 month duration. We determined if the magnitude of change in NT-proBNP over the treatment period was correlated with baseline parameters or nature/dose of TZD medication.Results: The subjects were 42% female and 58% male, and the mean age and duration was 59.8 ± 11.8 years old and 11.4 ± 8.3 years respectively. The baseline mean A1C and BMI was 8.7 ± 1.1% and 30.9 ± 8.7 ktifm2 respectively. We found that NT-proBNP levels did not vary significantly between baseline (mean ± SD: 143.8 ± 203.9 pg/mL) and 3 month follow-up (150.6 ± 186.2 pg/mL). Conversely, A1C levels declined significantly (pConclusion: Adding TZD therapy to patients with type 2 diabetes and no history of heart failure does not have a significant effect on NT-proBNP levels.